Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

被引：1

作者：

Fakih, Marwan

Cleary, James M.

Hong, Yong Sang

Kim, Tae-You

Safyan, Rachael A.

Allen, Simon

Bailey, Lorna

Cha, Edward

Lenain, Christelle

Lu, Danny

Schulze, Jochen

Shemesh, Colby S.

Zimmermann, Stefan

机构：

[1] City Hope Comprehens Med Ctr, Duarte, CA USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Seoul, South Korea

[5] Columbia Univ, Irving Med Ctr, New York, NY USA

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] Roche Prod Ltd, Welwyn Garden City, England

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[10] Univ Hosp Lausanne, Immunooncol Serv, Dept Oncol, Lausanne, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.3559

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3559

引用

页数：2

共 50 条

[21] phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS-pancreatic ductal adenocarcinoma
Chung, V.
Alistar, A.
George, B.
Kim, K.
Kindler, H.
Oh, D.
Allen, S.
Barak, H.
Ci, B.
Lau, J.
Retiere, A.
Shemesh, C.
Teichgraber, V.
Zhang, X.
Lopez, C.
ANNALS OF ONCOLOGY, 2020, 31 : S218 - S218
[22] Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
Liu, Rui
Ji, Zhi
Wang, Xia
Zhu, Lila
Xin, Jiaqi
Ma, Lijun
Zhang, Jiayu
Ge, Shaohua
Zhang, Le
Yang, Yuchong
Ning, Tao
Bai, Ming
Duan, Jingjing
Wang, Feixue
Sun, Yansha
Li, Hongli
Deng, Ting
Ba, Yi
Hao, Jihui
NATURE COMMUNICATIONS, 2025, 16 (01)
[23] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
Falcone, A.
Cremolini, C.
Loupakis, F.
Lonardi, S.
Casagrande, M. E.
Murgioni, S.
Salvatore, L.
Masi, G.
Fanotto, V.
Granetto, C.
Marmorino, F.
Ginocchi, L.
Ziampiri, S.
Grande, R.
Tonini, G.
Delfanti, S.
Di Donato, S.
Fontanini, G.
Boni, L.
Zagonel, V.
ANNALS OF ONCOLOGY, 2016, 27
[24] Atezolizumab and bevacizumab (atezo plus bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)eexperienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Ghiringhelli, F.
Felip, E.
Zer, A.
Greillier, L.
Greystoke, A.
Al-Sakaff, N.
Helms, H-J.
Pintoffl, J. P.
Rahalkar, S.
Lim, F. L.
Cho, B. C.
ANNALS OF ONCOLOGY, 2023, 34
[25] Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) plus entinostat (entino) in MORPHEUS-HR plus breast cancer (M-HR plus BC)
Sonnenblick, A.
Im, S-A.
Lee, K. S.
Tan, A.
Telli, M.
Shachar, S. Strulov
Tchaleu, F. Bene
Cha, E.
DuPree, K.
Nikanjam, M.
Shemesh, C.
Xu, J.
Zhang, X.
Zhu, J.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2021, 32 : S479 - S479
[26] Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial
Salvatore, Lisa
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Bergamo, Francesca
Gallano, Antonella
Zagonel, Vittorina
Ferrari, Laura
Ongaro, Elena
Cardellino, Giovanni
Marcucci, Lorenzo
Lucchesi, Sara
Banzi, Maria
Ciarlo, Andrea
Miraglio, Emanuele
Delfanti, Sara
Corsi, Domenico C.
Zaniboni, Alberto
Tonlni, Giuseppe
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] A phase II study of cadonilimab plus FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Lin, R.
Zhao, S.
Su, L.
Hong, Y.
Luo, J.
Wei, Y.
Zhao, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1519 - S1519
[28] Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Drakaki, Alexandra
Powles, Thomas
Bamias, Aristotelis
Martin-Liberal, Juan
Shin, Sang Joon
Friedlander, Terence
Tosi, Diego
Park, Chandler
Gomez-Roca, Carlos
Lobbedez, Florence Joly
Castellano, Daniel
Morales-Barrera, Rafael
Moreno-Candilejo, Irene
Flechon, Aude
Yuen, Kobe
Rishipathak, Deepali
Dupree, Kelly
Young, Fiona
Michielin, Francesca
Shemesh, Colby S.
Steinberg, Elizabeth E.
Williams, Patrick
Lee, Jae Lyun
CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4373 - 4384
[29] Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379)
Almhanna, Khaldoun
Breakstone, Rimini
Raufi, Alexander
Wood, Roxanne
Webber, Amy
Dionson, Sopha
Cavanagh, Lindsay
Seyhan, Attila A.
Safran, Howard
El-Deiry, Wafik
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
[30] Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
Finn, Richard S.
Ryoo, Baek-Yeol
Hsu, Chih-Hung
Li, Daneng
Burgoyne, Adam
Cotter, Christopher
Badhrinarayanan, Shreya
Wang, Yulei
Yin, Anqi
Edubilli, Tirupathi Rao
Gane, Edward
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →